139 results on '"D. Pouessel"'
Search Results
2. EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial
- Author
-
L Perrier, O Tredan, M Morelle, N Penel, P Fournel, L Greillier, F Ghiringhelli, D Tosi, F Bertucci, M Campone, JP Delord, D Pouessel, G Garin, S Chabaud, C Gomez-Roca, D Pannier, M Brahmi, M Fabbro, ME Garcia, I Ray-Coquard, M Viala, A Italiano, P Cassier, A Dufresne, V Attignon, I Treilleux, A Viari, T de la Motte Rouge, X Durando, D Perol, JY Blay, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), and École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Health Policy ,Public Health, Environmental and Occupational Health ,[SHS]Humanities and Social Sciences - Abstract
International audience
- Published
- 2022
3. Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A study of the EAU Young Academic Urologists urothelial carcinoma working group
- Author
-
G. Marcq, W. Kassouf, M. Roumiguié, B. Pradere, S. Albisinni, A. Cimadamore, J.Y. Teoh, M. Moschini, E. Laukhtina, A. Mari, F. Soria, A. Gallioli, J.B. Beauval, E. Xylinas, D. Pouessel, P. Sargos, and G. Ploussard
- Subjects
Urology - Published
- 2023
4. [Bladder-sparing trimodal therapy for muscle invasive bladder cancer]
- Author
-
J, Khalifa, M, Roumiguié, D, Pouessel, and P, Sargos
- Subjects
Urinary Bladder Neoplasms ,Muscles ,Urinary Bladder ,Quality of Life ,Humans ,Neoplasm Invasiveness ,Cystectomy ,Combined Modality Therapy ,Organ Sparing Treatments - Abstract
Organ-sparing strategies in the management of local or locally advanced cancers meet a dual objective: tumor control and preservation of the function of the involved organ. Given the morbidity and mortality of cystectomy and its impact on quality of life and bladder function, bladder-sparing strategies have emerged for the management of urothelial muscle invasive bladder cancer, mostly through trimodal treatment, which consists in maximal trans-urethral resection of bladder tumor, followed by chemo-radiotherapy. This review presents the modalities of trimodal treatment, before exposing the advantages and limitations of this strategy compared to cystectomy among operable patients. Despite the absence of comparative data from randomized trials, the two approaches seem to provide similar oncological results among appropriately selected patients. In modern series, the rate of salvage cystectomy is approximately 15% at 5 years; this delayed cystectomy does not seem to be associated with greater morbidity and mortality as compared to upfront cystectomy. Emphasis is placed in the review on quality of life data of these two approaches. In order to optimize the selection of patients eligible to trimodal therapy, the classical predictive factors of response to radio(chemo)therapy are critically analyzed, with the perspective of innovative molecular biomarkers. Finally, a close multidisciplinary collaboration is needed for the choice and the execution of the therapeutic strategy, and the patient should be fully involved in the decision-making process.
- Published
- 2022
5. 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
- Author
-
P. Barthelemy, C. Thibault, E. Voog, J-C. Eymard, A. Ravaud, A. Flechon, C. Abraham Jaillon, W. Hilgers, S. Le Moulec, M. Chasseray, D. Pouessel, Y.E. Amela, V. Lorgis, E. Nicolas, E. Kazan, G. Denechere, M-N. Solbes, P. Lambert, and Y. Loriot
- Subjects
Oncology ,Hematology - Published
- 2022
6. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
- Author
-
S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, Pulmonary medicine, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, University of Zurich, and Stahel, R A
- Subjects
Male ,medicine.medical_specialty ,Lung Neoplasms ,2720 Hematology ,MULTICENTER ,610 Medicine & health ,Ipilimumab ,Randomised clinical trial ,randomised clinical trial ,1ST-LINE NIVOLUMAB ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,small-cell lung cancer ,Humans ,RECURRENT ,ipilimumab ,Lung cancer ,nivolumab ,Limited disease ,Performance status ,Small cell lung cancer ,business.industry ,Standard treatment ,Hazard ratio ,PLUS IPILIMUMAB ,SCLC ,Hematology ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,OPEN-LABEL ,Nivolumab ,Oncology ,10032 Clinic for Oncology and Hematology ,limited disease ,CHECKMATE 032 ,2730 Oncology ,Female ,Prophylactic cranial irradiation ,business ,medicine.drug - Abstract
BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATIENTS AND METHODS: STIMULI is a 1:1 randomised phase II trial aiming to demonstrate superiority of consolidation combination immunotherapy versus observation after chemo-radiotherapy plus PCI (protocol amendment-1). Consolidation immunotherapy consisted of four cycles of nivolumab [1 mg/kg, every three weeks (Q3W)] plus ipilimumab (3 mg/kg, Q3W), followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months. Patient recruitment closed prematurely due to slow accrual and the statistical analyses plan was updated to address progression-free survival (PFS) as the only primary endpoint. RESULTS: Of the 222 patients enrolled, 153 were randomised (78: experimental; 75: observation). Among the randomised patients, median age was 62 years, 60% males, 34%/65% current/former smokers, 31%/66% performance status (PS) 0/1. Up to 25 May 2020 (median follow-up 22.4 months), 40 PFS events were observed in the experimental arm, with median PFS 10.7 months [95% confidence interval (CI) 7.0-not estimable (NE)] versus 42 events and median 14.5 months (8.2-NE) in the observation, hazard ratio (HR)= 1.02 (0.66-1.58), two-sided P= 0.93. With updated follow-up (03 June 2021; median: 35 months), median OS was not reached in the experimental arm, while it was 32.1 months (26.1-NE) in observation, with HR= 0.95 (0.59-1.52), P= 0.82. In the experimental arm, median time-to-treatment-discontinuation was only 1.7 months. CTCAE v4 grade =3 adverse events were experienced by 62% of patients in the experimental and 25% in the observation arm, with 4 and 1 fatal, respectively. CONCLUSIONS: The STIMULI trial did not meet its primary endpoint of improving PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in LD-SCLC. A short period on active treatment related to toxicity and treatment discontinuation likely affected the efficacy results.
- Published
- 2021
7. Résultats oncologiques des patients présentant une atteinte ganglionnaire à la suite d’une chimiothérapie néoadjuvante et d’une cystectomie totale pour un cancer de la vessie infiltrant le muscle : une étude observationnelle multicentrique du groupe de travail sur le carcinome urothélial de l’eau young academic urologists (YAU)
- Author
-
G. Marcq, W. Kassouf, M. Roumiguié, B. Pradere, J. Beauval, E. Xylinas, D. Pouessel, P. Sargos, and G. Ploussard
- Subjects
Urology - Published
- 2022
8. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
- Author
-
M. Haberstich, G. Pignot, J. Rigaud, M. Cancel, D. Maillet, S. Oudard, D. Pouessel, C. Serrate, L. Campedel, C. Dumont, D. Borchiellini, P. Barthelemy, E. Boughalem, E. Colomba, O. Huillard, H.J. Boyle, F. Lefort, F. Constans Schlurmann, F. Audenet, and C. Thibault
- Subjects
Oncology ,Hematology - Published
- 2022
9. 700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
- Author
-
P. Beuzeboc, Manojkumar Bupathi, Rohit Jain, Y. Pan, J.M. Jürgensmeier, Philippe Barthélémy, Y. Loriot, Arash Rezazadeh, Petros Grivas, Cora N. Sternberg, Arjun Vasant Balar, Phillip L. Palmbos, Christos Kyriakopoulos, Aude Flechon, Neeraj Agarwal, D. Pouessel, Daniel P. Petrylak, Scott T. Tagawa, and T. Goswami
- Subjects
Oncology ,Antigen ,business.industry ,Sacituzumab govitecan ,Cancer research ,Urothelial cancer ,Medicine ,In patient ,Hematology ,Trophoblast cell ,business - Published
- 2021
10. 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
- Author
-
Diane Pannier, S.B. Esma, O. Dereure, L. Gambotti, D. Pouessel, C. Simon, D. Tosi, M. De Pontville, F. Legrand, Marie Beylot-Barry, Aurélien Marabelle, Sylvie Chevret, E. Coquan, Céline Gavoille, Aude Flechon, François Ghiringhelli, Hakim Mahammedi, J-P. Spano, P. Augereau, and Assia Lamrani-Ghaouti
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Penile squamous cell carcinoma ,Internal medicine ,Cohort ,Medicine ,Hematology ,Nivolumab ,business - Published
- 2021
11. NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
- Author
-
Cheng-Ming Sun, Arnaud Mejean, M. Rouabah, D. Borchiellini, Stéphane Oudard, François Audenet, Philippe Barthélémy, Nicolas Pallet, D. Pouessel, Virginie Verkarre, I. Helali, Aude Flechon, Catherine Sautès-Fridman, Hélène Blons, Constance Thibault, Olivier Huillard, and R. Elaidi
- Subjects
medicine.medical_specialty ,Durvalumab ,Standard of care ,business.industry ,Immune checkpoint inhibitors ,Muscle invasive ,Hematology ,Clinical trial ,Oncology ,Family medicine ,medicine ,In patient ,business ,Tremelimumab ,medicine.drug ,Urothelial carcinoma - Abstract
Background Neoadjuvant cisplatin-based chemotherapy (NAC) is the standard of care in non-metastatic muscle-invasive bladder cancer (MIBC). However, 60-75% patients have residual tumor after neoadjuvant cisplatin-gemcitabin or ddMVAC regimen. Pathological complete response (pCR) after NAC is correlated with overall survival (OS). Based on the overall response rate observed in the metastatic setting, ddMVAC is the most commonly used NAC regimen in Europe in urothelial carcinoma (UC) in fit patients. The emergence of immune checkpoint inhibitor (ICI) in the metastatic setting raises the question if the combination chemo plus ICI could increase the pCR rate. Trial design NEMIO is a French open-label randomized phase II trial assessing in the neoadjuvant setting the combination ddMVAC plus durvalumab (D) alone or in combination with tremelimumab (T): 4 cycles of ddMVAC every 2 weeks + 2 cycles of D (1500 mg) +/- T (75 mg) every 4 weeks. Cystectomy is performed 4-8 weeks after the last dose of ddMVAC. As no safety data are available on the ICI plus ddMVAC combination, 6 pts will be included in each arm in a safety run-in cohort to evaluate the toxicity rate of the 2 regimens. Each arm will be expanded to a maximum of 60 pts according to a Bayesian stopping rule based on grade 3/4 treatment-related adverse events (G 3/4 TRAE). The primary endpoint of the safety run-in phase will be the rate of G3/4 TRAE. The primary endpoint of the phase II will be the pCR rate and G3/4 TRAE. We hypothesized that pCR after ddMVAC + D +/- T will be > or = 45%. Exploratory endpoints will include biomarkers of response and resistance to the combo. Molecular analysis will be conducted on tumor, blood (ctDNA) and urine samples (uDNA). Immunological and metabolomics profile will also be analyzed. Seven patients have yet been enrolled since December 2018 from the 10 French participating centers and we expect the recruitment to be completed in 2021. Clinical trial identification NCT03549715. Legal entity responsible for the study Association pour la Recherche de Therapeutiques Innovantes en Cancerologie (ARTIC). Funding AstraZeneca. Disclosure C. Thibault: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer. D. Borchiellini: Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Ipsen. O. Huillard: Honoraria (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self): Janssen. P. Barthelemy: Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy: MSD; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Sanofi. D. Pouessel: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Incyte. A. Flechon: Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD. H. Blons: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer; Advisory / Consultancy: MSD. S. Oudard: Honoraria (self): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Roche. All other authors have declared no conflicts of interest.
- Published
- 2019
12. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
- Author
-
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, and K Yakendji
- Subjects
Adult ,medicine.medical_specialty ,Receptor, ErbB-2 ,Population ,Breast Neoplasms ,030204 cardiovascular system & hematology ,Drug Administration Schedule ,law.invention ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Breast cancer ,Antineoplastic Agents, Immunological ,Randomized controlled trial ,Trastuzumab ,law ,Internal medicine ,medicine ,Adjuvant therapy ,Humans ,030212 general & internal medicine ,skin and connective tissue diseases ,education ,Infusions, Intravenous ,Aged ,education.field_of_study ,business.industry ,Hazard ratio ,General Medicine ,Middle Aged ,Interim analysis ,medicine.disease ,Survival Analysis ,Treatment Outcome ,Chemotherapy, Adjuvant ,Concomitant ,Female ,France ,business ,medicine.drug - Abstract
Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned final analysis based on the prespecified number of occurring events. Methods PHARE is an open-label, phase 3, non-inferiority randomised trial of patients with HER2-positive early breast cancer comparing 6 months versus 12 months of trastuzumab treatment concomitant with or following standard neoadjuvant or adjuvant chemotherapy. The study was undertaken in 156 centres in France. Eligible patients were women aged 18 years or older with non-metastatic, operable, histologically confirmed adenocarcinoma of the breast and either positive axillary nodes or negative axillary nodes but a tumour of at least 10 mm. Participants must have received at least four cycles of a chemotherapy for this breast cancer and have started receiving adjuvant trastuzumab-treatment. Eligible patients were randomly assigned to either 6 months or 12 months of trastuzumab therapy duration between the third and sixth months of adjuvant trastuzumab. The randomisation was stratified by concomitant or sequential treatment with chemotherapy, oestrogen receptor status, and centre. The primary objective was non-inferiority in the intention-to-treat population in the 6-month group in terms of disease-free survival with a prespecified hazard margin of 1·15. This trial is registered with ClinicalTrials.gov, number NCT00381901. Findings 3384 patients were enrolled and randomly assigned to either 12 months (n=1691) or 6 months (n=1693) of adjuvant trastuzumab. One patient in the 12-month group and three patients in the 6-month group were excluded, so 1690 patients in each group were included in the intention-to-treat analysis. At a median follow-up of 7·5 years (IQR 5·3–8·8), 704 events relevant to disease-free survival were observed (345 [20·4%] in the 12-month group and 359 [21·2%] in the 6-month group). The adjusted hazard ratio for disease-free survival in the 12-month group versus the 6-month group was 1·08 (95% CI 0·93–1·25; p=0·39). The non-inferiority margin was included in the 95% CI. No differences in effects pertaining to trastuzumab duration were found in any of the subgroups. After the completion of trastuzumab treatment, rare adverse events occurred over time and the safety analysis remained similar to the previously published report. In particular, we found no change in the cardiac safety comparison, and only three additional cases in which the left ventricular ejection fraction decreased to less than 50% have been reported in the 12-month group. Interpretation The PHARE study did not show the non-inferiority of 6 months versus 12 months of adjuvant trastuzumab. Hence, adjuvant trastuzumab standard duration should remain 12 months. Funding The French National Cancer Institute.
- Published
- 2019
13. LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
- Author
-
L.M. Itri, T. Goswami, Arjun Vasant Balar, Scott T. Tagawa, Neeraj Agarwal, Daniel P. Petrylak, Phillip L. Palmbos, Philippe Barthélémy, Christos Kyriakopoulos, Aude Flechon, Petros Grivas, Arash Rezazadeh, Y. Loriot, Cora N. Sternberg, P. Beuzeboc, Manojkumar Bupathi, Q. Hong, D. Pouessel, and Rohit Jain
- Subjects
Oncology ,business.industry ,Immune checkpoint inhibitors ,Cohort ,Sacituzumab govitecan ,Cancer research ,Urothelial cancer ,Medicine ,Phases of clinical research ,Hematology ,business - Published
- 2020
14. 1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
- Author
-
C. Thibault, R.T. Elaidi, D. Pouessel, A. Fléchon, D. Borchiellini, P. Barthélémy, O. Huillard, M. Rouabah, E. Braychenko, I. Helali, F. Audenet, and S. Oudard
- Subjects
Oncology ,Hematology - Published
- 2020
15. 526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
- Author
-
F. Legrand, N. Hoog-Labouret, Frederic Rolland, P. Augereau, O. Bouche, Romain Cohen, Julien Masliah-Planchon, Ivan Bièche, B.J-C. Rousseau, C. Simon, N. Hamzaoui, Eric Pasmant, Sylvie Chevret, J.-J. Grob, A. Lamrani-Ghaouti, Esma Saada-Bouzid, D. Pouessel, V. Simmet, Aurélien Marabelle, and A. Bruyas
- Subjects
Oncology ,business.industry ,Cancer research ,High activity ,Medicine ,In patient ,DNA mismatch repair ,Hematology ,Nivolumab ,business ,Domain (software engineering) - Published
- 2020
16. High level of activity of nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
- Author
-
T. Andre, Esma Saada-Bouzid, C. Le Tourneau, Benoist Chibaudel, Stéphane Oudard, P. Augereau, C. Simon, Jean-Charles Soria, D. Pouessel, Aurélien Marabelle, Christophe Tournigand, D. Couch, Sylvie Chevret, J.-J. Grob, N. Hoog-Labouret, Aude Flechon, C. Tiffon, and Marie Beylot-Barry
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Anti pd 1 ,Stock options ,Hematology ,Non colorectal ,Oncology ,Family medicine ,Cohort ,medicine ,Favorable outcome ,Nivolumab ,Until Disease Progression ,education ,business ,health care economics and organizations - Abstract
Background Microsatellite instability-high (MSI-H) is observed in a large variety of cancer types. Immune checkpoint targeted therapies against PD-1 and CTLA-4 have demonstrated significant activity in metastatic colorectal cancer (mCRC) with nivolumab +/- ipilimumab. We aimed to demonstrate a clinical benefit of nivolumab in non-CRC MSI patients. Methods The AcSe immunotherapy program launched by the French National Cancer Institute (INCa) and sponsored by the French network of comprehensive cancer centers (Unicancer) is a nationwide exploratory program which has allowed access to anti-PD-1 therapies outside of their current approvals. A phase II, single arm, AcSe-nivolumab trial has been conducted to investigate the efficacy and tolerance of nivolumab in patients with metastastic/refractory rare tumor types. Here we report the results of the MSI cohort. Nivolumab (240 mg IV) was administered q2w for a max of 2 years or until disease progression (PD), or toxicity. The primary endpoint was the objective response rate (ORR) assessed by RECIST v1.1 at 12 weeks. Results From July 2017 to October 2018, 50 pts (mean age 63 years) were included. Primary locations were endometrial adenoCa (17), gastric (10), small bowel (7), pancreas (5), biliary (4), urothelial (2), ovary (2), and breast (2). 15 patients (30%) had a Lynch syndrome. All patients were pre-treated (mean of previous lines: 1.6) and had a MSI status locally determined by IHC and/or PCR (IHC 15 pts, PCR 4, both 31). The mean number of cycles/patients was 12.9. The ORR at 12 weeks was 38% (95%CI 24.6 to 52.8) and the best ORR at any time was 42% (95%CI, 28.2 to 56.8) with median time to response of 14 weeks. CR: n = 2; PR: n = 17; SD: n = 16; DCR=74%. Median PFS was not reached with a 6-mo PFS at 58.9% (95%CI, 46.5 to 74.6). At the date of analysis, 15 patients died (PD 13, drug related death 1, other 1), with a 6-mo OS rate at 80.3% (95%CI, 69.5 to 92.8). No unexpected adverse event of nivolumab has been observed. Conclusions Nivolumab as monotherapy is highly active in non-colorectal MSI patients, outperforming results of classical chemotherapy in this heavily pre-treated population. Clinical trial identification NCT03012581, EudraCT 2016-002257-37. Legal entity responsible for the study RD Honoraria (institution), Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (institution), Travel / Accommodation / Expenses: BMS. E. Saada-Bouzid: Advisory / Consultancy: BMS; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Merck Serono. D. Pouessel: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Astellas; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): A2; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: BMS. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Nanobiotix; Advisory / Consultancy: Roche; Advisory / Consultancy: Amgen; Advisory / Consultancy: GSK. P. Augereau: Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca. J. Soria: Advisory / Consultancy, Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca; Shareholder / Stockholder / Stock options: Gritstone; Advisory / Consultancy: Astex; Advisory / Consultancy: Clovis; Advisory / Consultancy: GSK; Advisory / Consultancy: GammaMabs; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Mission Therapeutics; Advisory / Consultancy: Merus; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Servier; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Takeda. A. Marabelle: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): BMS; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Funding (self): Fondation MSD Avenir; Advisory / Consultancy: Oncovir; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Serono; Advisory / Consultancy: eTheRNA; Advisory / Consultancy, Research grant / Funding (self): Lytix pharma; Advisory / Consultancy: Kyowa Kirin Pharma; Advisory / Consultancy: Novartis, Seattle Genetics, Molecular Partners; Advisory / Consultancy: Symphogen, Bayer, Partner Therapeutics; Advisory / Consultancy: Genmab, RedX pharma, OSE Immunotherapeutics; Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen, Sanofi, Servier; Advisory / Consultancy: Biothera, Gritstone; Advisory / Consultancy: Nektar, Pierre Fabre; Advisory / Consultancy: GSK; Advisory / Consultancy: Oncosec; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Speaker Bureau / Expert testimony, Research grant / Funding (self): MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca/MedImmune; Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche/Genentech. All other authors have declared no conflicts of interest.
- Published
- 2019
17. FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
- Author
-
L.S. Mertens, B.W.G. Van Rhijn, R. Mayr, P.J. Bostrom, M. Marquez, E.C. Zwarthoff, J.L. Boormans, C. Abas, G. Van Leenders, Y. Neuzillet, M.S. Van Der Heijden, F.X. Real, R. Stohr, A.R. Zlotta, M. Eckstein, Y. Soorojebally, M. Burger, F. Radvanyi, N. Sirab, D. Pouessel, T.H. Van Der Kwast, N. Malats, A. Hartmann, Y. Allory, and T. Zuiverloon
- Subjects
Urology - Published
- 2019
18. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort
- Author
-
Stéphane Culine, Nadine Houede, Alexandre de la Taille, Yves Allory, Dimitri Vordos, Yohann Loriot, Aurélie Le Thuaut, Christine Chevreau, Emmanuel Sevin, Sylvie Bastuji-Garin, Philippe Beuzeboc, D. Pouessel, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Laboratoire d'Investigation Clinique (LIC), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de santé publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service d'urologie [Mondor], Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Claudius Regaud, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Curie [Paris], Département de pathologie [Mondor], Université Paris Diderot - Paris 7 (UPD7), Service d'hématologie et oncologie médicale, Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Hôpital Henri Mondor, Institut Bergonié [Bordeaux], UNICANCER, Oncologie génito-urinaire, Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Institut Jérôme Lejeune, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10
- Subjects
Oncology ,Male ,medicine.medical_treatment ,030232 urology & nephrology ,Deoxycytidine ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,Carboplatin ,chemistry.chemical_compound ,0302 clinical medicine ,Postoperative chemotherapy ,Antineoplastic Combined Chemotherapy Protocols ,Stage (cooking) ,ComputingMilieux_MISCELLANEOUS ,Aged, 80 and over ,Hazard ratio ,Middle Aged ,Prognosis ,3. Good health ,Vinblastine ,Treatment Outcome ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Cohort ,Female ,Urothelial carcinoma ,France ,medicine.drug ,Adult ,medicine.medical_specialty ,Survivals ,Urology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Cystectomy ,Disease-Free Survival ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Bladder cancer ,business.industry ,Bladder carcinoma ,medicine.disease ,Survival Analysis ,Gemcitabine ,Methotrexate ,chemistry ,Urinary Bladder Neoplasms ,Doxorubicin ,Cisplatin ,business - Abstract
International audience; BACKGROUND:In the past decade, adjuvant chemotherapy (AC) after radical cystectomy (RC) was preferred worldwide for patients with muscle-invasive urothelial bladder cancer. In this study we aimed to determine the outcome of patients who received AC and evaluated prognostic factors associated with survival.PATIENTS AND METHODS:We retrospectively analyzed 226 consecutive patients treated in 6 academic hospitals between 2000 and 2009. Multivariate Cox proportional hazards regression adjusted for center to estimate adjusted hazard ratios (HRs) with 95% confidence intervals were used.RESULTS:The median age was 62.4 (range, 35-82) years. Patients had pT3/pT4 and/or pN+ in 180 (79.6%) and 168 patients (74.3%), respectively. Median lymph node (LN) density was 25% (range, 3.1-100). Median time between RC and AC was 61.5 (range, 18-162) days. Gemcitabine with cisplatin, gemcitabine with carboplatin, and MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were delivered in 161 (71.2%), 49 (21.7%), and 12 patients (5.3%) of patients, respectively. The median number of cycles was 4 (range, 1-6). Thirteen patients (5.7%) with LN metastases also received adjuvant pelvic radiotherapy (ART). After a median follow-up of 4.2 years, 5-year overall survival (OS) was 40.7%. In multivariate analysis, pT ≥3 stage (HR, 1.73; P = .05), LN density >50% (HR, 1.94; P = .03), and number of AC cycles
- Published
- 2017
19. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
- Author
-
Aude Flechon, D. Pouessel, X. Zhu, E. Asatiani, Hui-Ling Zhen, Sumati Gupta, Michele Maio, Andrea Necchi, G. Serbest, Philippe Barthélémy, Yohann Loriot, and Raya Leibowitz-Amit
- Subjects
0301 basic medicine ,CARCINOMA TRANSITIONAL CELL ,business.industry ,Hematology ,Fibroblast growth factor ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Multicenter study ,Fibroblast growth factor receptor ,030220 oncology & carcinogenesis ,Cancer research ,Medicine ,In patient ,FGF Receptor ,Open label ,business ,Urothelial carcinoma - Published
- 2018
20. Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium
- Author
-
Nicolas Penel, A. Gobert, R. Elaidi, F. Estrade, M. Guerin, Stéphane Oudard, Remy Delva, Pernelle Lavaud, M.P. Tardy, Y. Neuzillet, M. Gross Goupil, N. Houede, M. Lorcet, Yves Allory, M. Sroussi, Philippe Barthélémy, D. Pouessel, E. Mussat, Olivier Huillard, and H. Gauthier
- Subjects
medicine.medical_specialty ,Urinary bladder ,business.industry ,030232 urology & nephrology ,Urology ,Hematology ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,medicine ,Neuroendocrine carcinoma ,business - Published
- 2018
21. Nouvelles hormonothérapies dans le cancer de la prostate
- Author
-
L. Quero, S. Culine, C. Hennequin, Pierre Mongiat-Artus, François Desgrandchamps, G. Bousquet, and D. Pouessel
- Subjects
Urology - Abstract
Resume Au cours des dernieres annees, la meilleure comprehension des mecanismes de resistance a la castration developpes par la cellule cancereuse prostatique a permis l’emergence de nouvelles classes d’hormonotherapie. Un premier antagoniste de LHRH, le degarelix, a obtenu une AMM dans le cancer de la prostate avance sensible a la castration. Plus recemment, l’acetate d’abiraterone, un inhibiteur du cytochrome CYP17, a montre une augmentation de la survie globale des patients metastatiques en phase refractaire a la castration apres docetaxel. Avant chimiotherapie, cette molecule conduit, dans des resultats precoces, a une augmentation de la survie sans progression radiologique. Une tendance au gain de survie globale semble se dessiner. Enfin, l’enzalutamide (MDV3100), antiandrogene de nouvelle generation, a egalement conduit a un benefice de survie des patients metastatiques pretraites par docetaxel. L’evaluation de ces nouveaux medicaments se poursuit a des stades plus precoces, ainsi que le developpement d’autres molecules des memes classes therapeutiques.
- Published
- 2012
22. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
- Author
-
Raheela Ashfaq, Patricia Harnden, A. De La Taille, Margaret A. Knowles, Yves Allory, A. Zlotta, Peter J. Boström, Annegien Broeks, Christine Chevreau, Dennis Peters, Yair Lotan, Pascale Maillé, Carolyn D. Hurst, S.F. Shariat, Pascale Soyeux, Dimitrios Vordos, S. Horenblas, Fannie Semprez, Yohann Loriot, P. Beuzeboc, B.W.G. Van Rhijn, T.H. Van Der Kwast, A. Manceau, Y. Neuzillet, Stéphane Culine, Tuomas Mirtti, Joyce Sanders, D. Pouessel, Darren C. Tomlinson, M.S. van der Heijden, Arthur I. Sagalowsky, Anissa Moktefi, Michael A.S. Jewett, J. De Jong, N. Houede, Maximilian Burger, Laura S. Mertens, Bharati Bapat, Karen Leroy, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service d'urologie [Mondor], Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département d'oncologie médicale, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Institut Claudius Regaud, Institut Curie [Paris], Département de pathologie [Mondor], and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Oncology ,Male ,medicine.medical_treatment ,030232 urology & nephrology ,Receptor tyrosine kinase ,Targeted therapy ,0302 clinical medicine ,Medicine ,bladder ,Neoadjuvant therapy ,biology ,Hematology ,Middle Aged ,targeted therapy ,3. Good health ,Gene Expression Regulation, Neoplastic ,030220 oncology & carcinogenesis ,Female ,musculoskeletal diseases ,Adult ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Clinical Decision-Making ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Cystectomy ,03 medical and health sciences ,Genetic Heterogeneity ,Internal medicine ,Biomarkers, Tumor ,cancer ,Humans ,Receptor, Fibroblast Growth Factor, Type 3 ,Perioperative Period ,Aged ,ta3126 ,Bladder cancer ,business.industry ,Genetic heterogeneity ,Cancer ,Original Articles ,Fibroblast growth factor receptor 3 ,ta3122 ,medicine.disease ,mutations ,stomatognathic diseases ,Urinary Bladder Neoplasms ,FGFR3 ,Mutation ,biology.protein ,Lymph Nodes ,heterogeneity ,business - Abstract
International audience; BACKGROUND:Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor is a candidate for personalized bladder cancer treatment, particularly in patients with mutated FGFR3. We addressed tumor heterogeneity in a large multicenter, multi-laboratory study, as this may have significant impact on therapeutic response.PATIENTS AND METHODS:We evaluated possible FGFR3 heterogeneity by the PCR-SNaPshot method in the superficial and deep compartments of tumors obtained by transurethral resection (TUR, n = 61) and in radical cystectomy (RC, n = 614) specimens and corresponding cancer-positive lymph nodes (LN+, n = 201).RESULTS:We found FGFR3 mutations in 13/34 (38%) T1 and 8/27 (30%) ≥T2-TUR samples, with 100% concordance between superficial and deeper parts in T1-TUR samples. Of eight FGFR3 mutant ≥T2-TUR samples, only 4 (50%) displayed the mutation in the deeper part. We found 67/614 (11%) FGFR3 mutations in RC specimens. FGFR3 mutation was associated with pN0 (P < 0.001) at RC. In 10/201 (5%) LN+, an FGFR3 mutation was found, all concordant with the corresponding RC specimen. In the remaining 191 cases, RC and LN+ were both wild type.CONCLUSIONS:FGFR3 mutation status seems promising to guide decision-making on adjuvant anti-FGFR3 therapy as it appeared homogeneous in RC and LN+. Based on the results of TUR, the deep part of the tumor needs to be assessed if neoadjuvant anti-FGFR3 treatment is considered. We conclude that studies on the heterogeneity of actionable molecular targets should precede clinical trials with these drugs in the perioperative setting.
- Published
- 2016
23. Side effects of androgen deprivation and their management
- Author
-
P. Mongiat-Artus, L. Quero, Christophe Hennequin, Stéphane Culine, and D. Pouessel
- Subjects
Oncology - Abstract
Les effets secondaires de la deprivation androgenique sont de mieux en mieux connus. A cote des bouffees de chaleur et de la dysfonction erectile, les complications cardiovasculaires et osseuses doivent etre prises en compte a la fois dans les indications des medicaments mais aussi dans la surveillance du traitement. L’induction d’un diabete peut etre un evenement precoce, survenant dans les six mois apres le debut du traitement. Les dyslipidemies sont plus rares. L’augmentation de la frequence des accidents cardiovasculaires ou de la mortalite cardiaque reste discutee. Il est maintenant bien demontre que la deprivation androgenique augmente de maniere moderee le risque d’evenements osseux de type osteoporotique. Cette meilleure connaissance des effets secondaires necessite la realisation d’un bilan clinique et paraclinique initial et lors de la surveillance d’une hormonotherapie prolongee.
- Published
- 2012
24. Castration resistance: pathophysiological mechanisms and therapeutic applications
- Author
-
Christophe Hennequin, D. Pouessel, L. Quero, Stéphane Culine, and P. Mongiat-Artus
- Subjects
Oncology - Abstract
Les connaissances acquises au cours de la derniere decennie ont permis de demontrer que le cancer de la prostate resistant a la castration (CPRC) demeure sensible aux traitements qui ciblent le recepteur aux androgenes (RA) et ses ligands. La synthese intracrine d’androgenes et l’augmentation d’expression du RA sont les principaux mecanismes qui participent a la croissance tumorale du CPRC. L’acetate d’abiraterone (AA) est un inhibiteur selectif du cytochrome P450 c17 (CYP17), une enzyme capitale intervenant dans la synthese des androgenes. Une etude de phase III a permis de demontrer un gain de survie chez les patients en echec d’une chimiotherapie prealable par docetaxel. Des resultats prometteurs ont ete obtenus dans une phase II avec le MDV3100, un antiandrogene de deuxieme generation, dont l’affinite pour le RA est plus grande que le bicalutamide, et qui limite sa translocation nucleaire, sa fixation sur l’ADN et le recrutement des coactivateurs de la transcription. Les etudes ulterieures devront determiner les sequences optimales d’utilisation de ces molecules, les possibilites d’association, ainsi que leur integration optimale parmi les nouveaux traitements emergents.
- Published
- 2012
25. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project
- Author
-
D. Quinn, Pascal Wolter, J. Fitzpatrick, Peter F.A. Mulders, S. Negrier, S. Crabb, David Pasquier, G. Gravis, Bertrand Tombal, Thomas Powles, Didier Jacqmin, Alessandro Volpe, A. Kramar, A. Ravaud, Alain Ravaud, S. Joniau, Timothy Eisen, Christophe Massard, Peter J. Goebell, J. Catto, Andrew Kramar, P.J. Goebell, C. Porta, James W.F. Catto, Elodie Vauleon, Alberto Bossi, T. Filleron, B. Melichar, David I. Quinn, E. Vauleon, Franck Bonnetain, Axel Bex, Simon J. Crabb, Thomas Filleron, Diego Tosi, Manuela Schmidinger, Sergio Braccarda, P. Nathan, R. Bukowski, Tim Eisen, D. Pasquier, R. Sylvester, Bernard Escudier, Ronald M. Bukowski, B. Malavaud, N. Houede, V. Flamand, A. Bex, T.K. Choueiri, Mounira El Demery, L. Mourey, D. Tosi, N. Houédé, P. Mulders, Richard Sylvester, Sylvie Negrier, P. Wolter, Gwendael Gravis, Bernard Malavaud, John M. Fitzpatrick, Vincent Flamand, T. Powles, A. Volpe, Paul Nathan, D. Pouessel, A. Bossi, Richard Kaplan, F. Rolland, R. Kaplan, F. Bonnetain, Frédéric Rolland, S. Bracarda, Camillo Porta, Damien Pouessel, M. Schmidinger, M. El Demery, D. Jacqmin, Loïc Mourey, Toni K. Choueiri, Bohuslav Melichar, Steven Joniau, B. Escudier, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Site de Recherche Intégrée en Cancérologie (SIRIC-ONCOLille), Université de Lille, Sciences et Technologies-Université de Lille, Sciences Humaines et Sociales-Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Medical Oncology [Lyon], Centre Léon Bérard [Lyon], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de radiothérapie [Gustave Roussy], Institut Gustave Roussy (IGR), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Lille Nord de France (COMUE), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Strasbourg, Service d'Urologie - Transplantation Rénale - Andrologie, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Département d'oncologie médicale, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-André, CRLCC René Gauducheau, Département d'oncologie Médicale, CRLCC Val d'Aurelle - Paul Lamarque, Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Université de Lille-UNICANCER, Université de Lille-UNICANCER-Université de Lille-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Oncology ,medicine.medical_specialty ,Delphi Technique ,Endpoint Determination ,Delphi method ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Disease ,renal cell cancer ,Disease-Free Survival ,time-to-event end points ,Renal cell carcinoma ,Internal medicine ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,Medicine ,Humans ,Carcinoma, Renal Cell ,Randomized Controlled Trials as Topic ,Protocol (science) ,clinical trials ,Surrogate endpoint ,business.industry ,Cancer ,Hematology ,medicine.disease ,Kidney Neoplasms ,3. Good health ,Surgery ,Clinical trial ,recommendations ,Guideline Adherence ,Neoplasm Recurrence, Local ,business ,Kidney cancer ,DATECAN - Abstract
Item does not contain fulltext BACKGROUND: In clinical trials, the use of intermediate time-to-event end points (TEEs) is increasingly common, yet their choice and definitions are not standardized. This limits the usefulness for comparing treatment effects between studies. The aim of the DATECAN Kidney project is to clarify and recommend definitions of TEE in renal cell cancer (RCC) through a formal consensus method for end point definitions. MATERIALS AND METHODS: A formal modified Delphi method was used for establishing consensus. From a 2006-2009 literature review, the Steering Committee (SC) selected 9 TEE and 15 events in the nonmetastatic (NM) and metastatic/advanced (MA) RCC disease settings. Events were scored on the range of 1 (totally disagree to include) to 9 (totally agree to include) in the definition of each end point. Rating Committee (RC) experts were contacted for the scoring rounds. From these results, final recommendations were established for selecting pertinent end points and the associated events. RESULTS: Thirty-four experts scored 121 events for 9 end points. Consensus was reached for 31%, 43% and 85% events during the first, second and third rounds, respectively. The expert recommend the use of three and two endpoints in NM and MA setting, respectively. In the NM setting: disease-free survival (contralateral RCC, appearance of metastases, local or regional recurrence, death from RCC or protocol treatment), metastasis-free survival (appearance of metastases, regional recurrence, death from RCC); and local-regional-free survival (local or regional recurrence, death from RCC). In the MA setting: kidney cancer-specific survival (death from RCC or protocol treatment) and progression-free survival (death from RCC, local, regional, or metastatic progression). CONCLUSIONS: The consensus method revealed that intermediate end points have not been well defined, because all of the selected end points had at least one event definition for which no consensus was obtained. These clarified definitions of TEE should become standard practice in all RCC clinical trials, thus facilitating reporting and increasing precision in between trial comparisons.
- Published
- 2015
26. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
- Author
-
P. Beuzeboc, P. Fargeot, Stéphane Culine, Jean-Pierre Droz, Gael Deplanque, Celine Ferlay, Aude Flechon, Florence Joly, D. Pouessel, Sylvie Zanetta, Gwenaelle Gravis, David Pérol, Stéphane Oudard, and Frank Priou
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Neoplasms, Hormone-Dependent ,Adenocarcinoma ,Neutropenia ,Neuroendocrine differentiation ,Disease-Free Survival ,Carboplatin ,chemistry.chemical_compound ,Neuroendocrine Cells ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,Etoposide ,business.industry ,Prostatic Neoplasms ,Bone metastasis ,Cell Differentiation ,Hematology ,medicine.disease ,Chemotherapy regimen ,Regimen ,chemistry ,Chromogranin A ,business ,Orchiectomy ,Febrile neutropenia ,medicine.drug - Abstract
Background In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine differentiation in 20% of cases. Patients and methods We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases. Patients received the combination of carboplatin and etoposide every 3 weeks. Efficacy end points included prostate-specific antigen (PSA) and neuroendocrine marker response, objective response and toxicity. Results Of the 60 patients included from April 2005 to January 2008, 78.6% had bone metastases, 46.4% had lymph node involvement and 57.1% had liver and/or lung localizations. The objective response rate was 8.9% in the 46 patients with measurable disease. A neuroendocrine response was observed in 31% of cases for NSE and 7% for CgA. The PSA response rate was 8%. The most common grade 3–4 treatment-related toxic effects were neutropenia (65.5%), thrombocytopenia (32.7%) and anemia (27.3%). There was 7.2% febrile neutropenia, with one toxicity-related death. The median follow-up was 9.3 months [95% confidence interval (CI) 0.2–27.1] and the median overall survival 9.6 months (95% CI 8.7–12.7). Conclusion The benefit–risk ratio of this regimen seems unfavorable due to poor response and high toxicity.
- Published
- 2011
27. Stratégies périopératoires dans les carcinomes urothéliaux de vessie infiltrant le muscle
- Author
-
Jean-Léon Lagrange, D. Pouessel, N. Mottet, Stéphane Culine, and J. Thariat
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Bladder cancer ,business.industry ,medicine.medical_treatment ,Combination chemotherapy ,Hematology ,General Medicine ,Perioperative ,medicine.disease ,Cystectomy ,Clinical trial ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,business ,Lymph node - Abstract
Radical cystectomy with bilateral pelvic lymph node dissection is the standard of care for patients with muscle-invasive bladder cancer, with 5-year survival rates not exceeding 60%. Consequently a multidisciplinary approach including perioperative chemotherapy and/or radiation therapy is required to improve these results. Data from clinical trials and meta-analyses with neoadjuvant chemotherapy have shown a significant benefit in overall survival, with a 5% absolute benefit at five years, provided cisplatin-based combination chemotherapy is used. Reported trials do not support the routine use of adjuvant chemotherapy. The current role of radiation therapy is limited to highly selected cases with a combination of external radiotherapy, partial cystectomy and interstitial brachytherapy.
- Published
- 2010
28. Medical treatment strategy in metastatic renal carcinoma
- Author
-
Jean-Jacques Patard, Stéphane Culine, and D. Pouessel
- Subjects
Gynecology ,Multikinase inhibitor ,Anti vegf ,medicine.medical_specialty ,Oncology ,Anticorps monoclonal ,business.industry ,Advanced stage ,medicine ,business ,Renal carcinoma - Abstract
Le cancer du rein localement avance ou metastatique a longtemps representeun difficile defi therapeutique en oncologie. Encore recemment, la prise en charge reposait sur l’immunotherapie mais conduisait rapidement a une impasse therapeutique. Les nouvelles therapies ciblant le vascular endothelial growth factor (VEGF) ou son recepteur (VEGF-R): sorafenib, sunitinib et bevacizumab ou mTOR (mammalian target of rapamycin): temsirolimus et everolimus ont transforme le pronostic et la qualite de vie de ces patients en quelques annees. La survie globale mediane rapportee dans certains essais est de 26 mois contre 10 a 12 mois a l’ere de l’immunotherapie. Les essais prospectifs randomises validant l’efficacite de ces medicaments permettent de bâtir, en 2009, un algorithme decisionnel afin de proposer aux patients une prise en charge optimale. Toutefois, certaines situations particulieres (metastases cerebrales, histologies papillaires ou chromophobes, patients âges, etc.) n’ont pas ou peu ete evaluees avec ces molecules, et le bien-fonde de leur prescription est alors en question. Leur tolerance et leur impact therapeutique seront etudies dans de futurs essais cliniques.
- Published
- 2009
29. Séminome de stade I, faut-il enterrer la radiothérapie ?
- Author
-
Stéphane Culine, D. Azria, and D. Pouessel
- Subjects
medicine.medical_specialty ,business.industry ,Adjuvant chemotherapy ,medicine.medical_treatment ,Treatment options ,Context (language use) ,Seminoma ,medicine.disease ,Carboplatin ,Surgery ,Radiation therapy ,chemistry.chemical_compound ,Oncology ,chemistry ,Medicine ,Combined Modality Therapy ,Radiology, Nuclear Medicine and imaging ,business ,Intensive care medicine ,Survival rate - Abstract
Postorchidectomy management of stage I testis seminoma has evolved for many years. Three treatment options should be discussed after surgery. Surveillance tends toward taking a more significant place to avoid overtreatment, adjuvant chemotherapy with carboplatin has demonstrated its efficiency, and for some, preventive radiotherapy, the historical reference treatment, is losing momentum. Whatever the chosen orientation, long-term prognosis is excellent with overall survival closed to 100%. In this context, this review underlines the advantages and the drawbacks of the three attitudes but also the unknowns relative to each. Indeed, their knowledge is crucial for informing clearly and with an objective way. Without gold-standard, but with three therapeutic options available, informing our patients is the key so they make an informed choice in dialogue with the oncologist.
- Published
- 2008
30. Création d’une unité de coordination de la prise en charge des tumeurs rares du rein de l’adulte
- Author
-
F. Thibault, Stéphane Oudard, D. Pouessel, A. Mejean, Alain Ravaud, Stéphane Culine, and A. Cassar
- Subjects
Oncology - Abstract
Les objectifs de ce reseau sont la mise en place d’une coordination nationale de prise en charge des tumeurs rares du rein de l’adulte. Cette unite s’est constituee autour de deux reunions de concertation pluridisciplinaire (RCP) regionales, l’une sur l’Ile-de-France et l’autre sur le Grand-Sud de facon a recenser, enregistrer et evaluer les traitements proposes a ces patients. L’objectif est de rediger un referentiel pour les tumeurs rares renales elaborees de facon multidisciplinaire afin de definir les modalites de diagnostic, de traitement et de surveillance. La constitution d’une tumorotheque et d’une serotheque, s’inscrivant dans la demande de l’institut du cancer, est mise en place afin d’identifier des marqueurs diagnostiques, pronostiques et predictifs de la reponse therapeutique aux anti-angiogeniques actuellement en cours d’evaluation. L’objectif final est d’obtenir des donnees epidemiologiques, cliniques et histologiques permettant de recenser les cas sur le plan national, de realiser un suivi de l’histoire naturelle, d’evaluer l’efficacite des traitements medicaux (anti-angiogeniques, inhibiteurs de mTOR [mammalian target of rapamycin]...) et chirurgicaux innovants et d’etre le support de publications de series homogenes sur le plan international.
- Published
- 2008
31. Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: a retrospective study from the GETUG (Groupe Etude des Tumeurs Uro Genitales)
- Author
-
D. Pouessel, N. Houede, Sophie Espenel, Sylvie Negrier, Philippe Barthélémy, Fabien Tinquaut, Laurence Albiges, E. Meriaux, C. Joly, Karim Fizazi, Aline Guillot, Hakim Mahammedi, M. Oriol, C. Vassal, Stéphane Culine, Christine Chevreau, G. Gravis, Guilhem Roubaud, and Sophie Tartas
- Subjects
0301 basic medicine ,Gynecology ,medicine.medical_specialty ,business.industry ,Anti angiogenic ,Urology ,Retrospective cohort study ,Hematology ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Denosumab ,Oncology ,Renal cell carcinoma ,030220 oncology & carcinogenesis ,medicine ,In patient ,business ,medicine.drug - Published
- 2016
32. Chemotherapy for Elderly Patients with Advanced Transitional Cell Carcinoma
- Author
-
Stéphane Culine and D. Pouessel
- Subjects
Oncology ,Cisplatin ,education.field_of_study ,medicine.medical_specialty ,Chemotherapy ,Performance status ,business.industry ,medicine.medical_treatment ,Population ,medicine.disease ,Chemotherapy regimen ,Gemcitabine ,Carboplatin ,chemistry.chemical_compound ,Transitional cell carcinoma ,chemistry ,Internal medicine ,Medicine ,education ,business ,medicine.drug - Abstract
Results from randomized trials allow concluding that cisplatin-based chemotherapy is the standard first-line treatment for patients with advanced transitional cell carcinoma of the urothelium. However, there is no standard chemotherapy regimen emerging from the literature for elderly patients as prospective studies dedicated to this population are quite rare. In daily practice, because of a better safety profile, the combination of gemcitabine and cisplatin (with G-CSF support) probably is the best choice to recommend in patients who are considered as fit for cisplatin. In patients with impaired renal function and good performance status, the combination of gemcitabine and carboplatin would be the most acceptable option. When performance status is poor, gemcitabine alone is an option along with best supportive care.
- Published
- 2012
33. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come]
- Author
-
I, Ouzaid, V, Ravery, D, Pouessel, and S, Culine
- Subjects
Male ,Radioisotopes ,Androstenols ,Clinical Trials as Topic ,Tissue Extracts ,Prostatic Neoplasms ,Antibodies, Monoclonal, Humanized ,Disease-Free Survival ,Survival Rate ,Treatment Outcome ,Clinical Trials, Phase III as Topic ,Antineoplastic Combined Chemotherapy Protocols ,Benzamides ,Nitriles ,Phenylthiohydantoin ,Humans ,Androstenes ,Taxoids ,France ,Denosumab ,Orchiectomy ,Radium ,Randomized Controlled Trials as Topic - Abstract
Recently, new agents have been developed in the treatment of prostate cancer. Our aim was to review phase III studies that involved novel agents in the treatment of castration resistant prostate cancer.PubMed databases were searched for original articles published with the search terms: prostate cancer, castration resistant, metastatic, targeted therapy, biologic agents, immunotherapy and clinical trials. Proceedings from 2008 of conferences of the American Society of Clinical Oncology, American Urological Association, and the European Association of Urology were also searched. We included phase III studies that involved: abiraterone, MDV 3100, cabazitaxel, sipuleucel-T, radium-223, and denosumab.Abiraterone and MDV 3100 are two new hormotherapies that showed an increased overall survival of 15 and 18 months respectively before after docetaxel based chemotherapy in randomized trials. Cabazitaxel became the standard second line chemotherapy after docetaxel. Sipuleucel-T has emerged as the first approved vaccine in prostate cancer. It showed a 22 % reduction of mortality and a prolonged survival time of 4.1 months compared to placebo. A radium-223 based metabolic radiotherapy has showed a better overall survival, delayed and reduced skeletal-related events in placebo controlled randomized trials. Denosumab also delayed the first skeletal-related event in a zoledronic acid controlled trial (20.7 versus 17.1 months, P=0.0002). Moreover, Denosumab delays bone metastases by 4.1 months compared to placebo.The novel agents that emerged in the treatment of prostate cancer showed an efficacy in placebo controlled trials. They added new tools in the armamentarium of therapies of castration resistant prostate cancer.
- Published
- 2012
34. Cancer du rein
- Author
-
D. Pouessel, Jean-Jacques Patard, and S. Culine
- Abstract
Le cancer du rein (CR) represente dans les pays occidentaux environ 3 % des cancers de l’adulte. Dans le monde, le nombre de nouveaux CR est estime a 189 000 par an. Son incidence est estimee aux Etats-Unis par l’American Cancer Society a 51 590 nouveaux cas en 2007 avec un sex-ratio en faveur des hommes (31 990 hommes pour 19 600 femmes). Le nombre de deces par cancer renal y est evalue a 12 890 par an [1]. En France, il represente le 8e cancer pour l’incidence et le 12e pour la mortalite. En 2005, 8 000 nouveaux cancers du rein ont ete diagnostiques, et pres de 4 000 deces etaient directement lies [2]. La part de cette localisation dans l’ensemble des cancers a legerement augmente entre 1980 et 2005 dans toutes les regions chez les hommes passant, en moyenne, de 2,6 % a 3,1 % des cas. Cette part est stable chez les femmes, passant de 1,6 % a 1,9 % au cours de cette periode. Le sex-ratio est de 2 hommes pour 1 femme, et l’âge median au diagnostic est de 67 ans chez l’homme et de 70 ans chez la femme. Le pic d’incidence est observe vers 70 ans. La forme la plus frequente est sporadique, mais quelques formes hereditaires ont ete identifiees a ce jour. Tous stades confondus, la survie est de 50 % a 10 ans. Mais un tiers des patients presentent des metastases d’emblee au diagnostic avec une mediane de survie plus sombre.
- Published
- 2011
35. [Advanced renal carcinomas with special situations. How to treat them?]
- Author
-
D, Pouessel, J-J, Patard, and S, Culine
- Subjects
Niacinamide ,Sirolimus ,Vascular Endothelial Growth Factor A ,Indoles ,Brain Neoplasms ,Pyridines ,Phenylurea Compounds ,TOR Serine-Threonine Kinases ,Benzenesulfonates ,Intracellular Signaling Peptides and Proteins ,Antibodies, Monoclonal ,Angiogenesis Inhibitors ,Protein Serine-Threonine Kinases ,Sorafenib ,Antibodies, Monoclonal, Humanized ,Kidney Neoplasms ,Bevacizumab ,Receptors, Vascular Endothelial Growth Factor ,Sunitinib ,Humans ,Pyrroles ,Everolimus ,Carcinoma, Renal Cell ,Aged - Abstract
Advanced or metastatic renal carcinoma represents a frequent disease in oncologic practice. Few years ago, in immunotherapy era, treatments had quickly reached deadlock. New therapies targeting vascular endothelial growth factors and their receptors (VEGF-R), sorafenib, sunitinib and bevacizumab, and the mammalian target of rapamycin (mTOR), temsirolimus and everolimus, have modified these patients prognosis and their quality of life in a few years. Nevertheless, patients included in randomized trials presented severe inclusion criteria. Then in the daily practice, patients have distinctive characteristics which were not evaluated in large pivotal studies: poor performance status, older patients, renal dysfunction, cerebral metastases or non clear cell renal cancer. In published trials, a few data concerning these situations are reported, and these studies have often included small samples, were retrospective or not randomised. However compared to global population, tolerance have not been very different in geriatric patients, or patients with poor performance status, or with central neurological metastases, or with papillary and chromophobe sub-types. On the contrary progression free or overall survivals increases are more difficult to confirm. Also before starting treatment, ratio between potential benefit and possible toxicities have to be evaluated. In patients with renal insufficiency, VEGF receptor inhibitors seem to be cautiously initiated at reduced doses, and to be increased according to tolerance. Due to these poor proof levels, clinical trials are needed for these specific populations.
- Published
- 2010
36. [Specificities of chemotherapy in elderly cancer patients]
- Author
-
C, Delbaldo, C, Delbado, P, Caillet, D, Pouessel, E, Paillaud, and S, Culine
- Subjects
Aging ,Urologic Neoplasms ,Humans ,Geriatric Assessment ,Aged - Abstract
The management of cancer in the elderly patients is becoming a major problem of public health. The population is becoming older, the risk of cancer is increasing with age and therapeutic tools are improving. The numerous pharmacological changes of age might influence the pharmacokinetic and pharmacodynamic variables of many drugs, in particular the agents of chemotherapy. The development of news drugs, with less toxicity, administrated weekly or orally, and of supportive care (hematological growth factors, nutritional support) allows proposing specific treatment to elderly patients with cancer. However, evidence-based medicine data are lacking to define optimal schedules in this population due to low inclusion rates in clinical trials. This paper explores the specificities of chemotherapy in elderly patients with cancer.
- Published
- 2010
37. [Prognostic factors in renal cell carcinoma]
- Author
-
N, Letang, L, Cabaniols, D, Pouessel, M, Robert, F, Iborra, S, Culine, J-J, Patard, J, Guiter, and R, Thuret
- Subjects
Nomograms ,Humans ,Neoplasm Invasiveness ,Prognosis ,Carcinoma, Renal Cell ,Kidney Neoplasms ,Neoplasm Proteins ,Neoplasm Staging ,Tumor Burden - Abstract
Identification of prognostic factors in renal cell carcinoma is very important today for three goals: providing patient information, giving appropriate treatments and selecting patients for adapted treatment schedules as well as new clinical trials. Prognostic factors in RCC include: anatomical (TNM classification), histological (Fuhrmann grade and histological subtype), clinical (symptoms and performance status) and molecular factors. For improving predicative accuracy of prognostic systems such as the TNM classification, new prognostic algorithms or nomograms have been designed combining independent prognostic variables. UISS and SSIGN are the 2 most effective prognostic systems within localized RCC. In metastatic disease, the two main systems that have been used for predicting response to immunotherapy are the model of the French Group of Immunotherapy and the Motzer model. With the arrivals of new molecular factors, these systems will perhaps have to evaluate: these new systems will require further validation as part of large prospective clinical trials.
- Published
- 2009
38. Les traitements antiangiogéniques modifient-ils ďhistoire naturelle de la maladie en phase métastasique?
- Author
-
D. Pouessel and Stéphane Culine
- Abstract
La constatation historique du caractere hypervascularise des cancers du rein a cellules claires suggerait ľexistence ďune importante proliferation vasculaire. Ľacquisition ulterieure des connaissances concernant les mecanismes moleculaires impliques dans la carcinogenese renale a confirme le role particulierement important de ľangiogenese dans le developpement tumoral renal. La preuve du concept a ete recemment apportee par la demonstration ďun benefice clinique en situation metastatique lors de ľutilisation de molecules ciblant les effecteurs de ľangiogenese. Dans ce chapitre, nous rappellerons les bases physiopathologiques de ľangiogenese tumorale et les mecanismes ďaction des molecules antiangiogeniques, puis nous developperons les resultats des essais cliniques ayant permis de valider ľutilisation de ces molecules dans la pratique quotidienne.
- Published
- 2008
39. Efficacité des antiangiogéniques dans le cancer du rein
- Author
-
S. Culine, D. Pouessel, and Jean-Jacques Patard
- Abstract
Le cancer du rein, dont ľincidence augmente depuis 50 ans, represente 2 a 3% des tumeurs malignes de ľadulte; et 85000 nouveaux cas environ sont repertories chaque annee en Europe, dont 8300 en France (1). Ľhistologie la plus frequente est representee par le carcinome a cellules claires, retrouvee dans 70 a 80% des cas, suivie des carcinomes papillaire (10 a 20%) et chromophobe (5%) (2). Un tiers de ces patients est diagnostique au stade ďemblee metastatique, et 30% des patients presentant une forme localisee initiale developperont des metastases apres la nephrectomie (3, 4). Les armes therapeutiques disponibles pour ces formes metastatiques de cancer du rein a cellules claires sont limitees. En effet, ce dernier est repute etre hormono- et chimioresistant. Les taux de reponse obtenus avec la majorite des cytotoxiques sont inferieurs a 10% dans la plupart des etudes publiees (5, 6). Jusqu’a present, le traitement standard du cancer du rein a cellules claires metastatique (CRM) reposait sur ľimmunotherapie, basee sur ľutilisation de deux cytokines: ľinterleukine 2 (IL2) et ľinterferon α (IFN-α). Mais peu de patients vont beneficier de ce traitement, c’est-a-dire obtenir une reponse prolongee (7, 8). En 2007, elle semble devoir etre reservee aux patients de bon pronostic. Malgre une prise en charge medicochirurgicale des CRM metastatiques, la survie globale mediane reste limitee a 10–12 mois (9), et le taux de survie a 5 ans est inferieur a 10% (10).
- Published
- 2008
40. [Stage I seminoma and radiotherapy: to bury it or not?]
- Author
-
D, Pouessel, S, Culine, and D, Azria
- Subjects
Male ,Survival Rate ,Testicular Neoplasms ,Humans ,Antineoplastic Agents ,Combined Modality Therapy ,Orchiectomy ,Carboplatin ,Neoplasm Staging ,Seminoma - Abstract
Postorchidectomy management of stage I testis seminoma has evolved for many years. Three treatment options should be discussed after surgery. Surveillance tends toward taking a more significant place to avoid overtreatment, adjuvant chemotherapy with carboplatin has demonstrated its efficiency, and for some, preventive radiotherapy, the historical reference treatment, is losing momentum. Whatever the chosen orientation, long-term prognosis is excellent with overall survival closed to 100%. In this context, this review underlines the advantages and the drawbacks of the three attitudes but also the unknowns relative to each. Indeed, their knowledge is crucial for informing clearly and with an objective way. Without gold-standard, but with three therapeutic options available, informing our patients is the key so they make an informed choice in dialogue with the oncologist.
- Published
- 2008
41. 7021 POSTER Multidisciplinary Management of Castration Resistant Prostate Cancer (CRPC) in France – a Survey Comparing Practices and Assessing Collaboration Between Urologists and Oncologists
- Author
-
T de La Motte Rouge, D. Pouessel, F. Thibault, N. Gillion, F. Dubosq, A. Benchikh, X. Durand, I. Alexandre, and A. Plantade
- Subjects
Oncology ,Cancer Research ,Prostate cancer ,medicine.medical_specialty ,Multidisciplinary approach ,business.industry ,Internal medicine ,Family medicine ,medicine ,Castration resistant ,medicine.disease ,business - Published
- 2011
42. Poussées de dermatomyosite associées à des cancers différents chez un même malade
- Author
-
Martine Bagot, G. Hickman, D. Pouessel, C. Vanhaecke, and Antoine Petit
- Subjects
Dermatology - Published
- 2012
43. Thérapeutiques ciblées dans la neurofibromatose 1 : les premières avancées
- Author
-
J.-Y. Bley, P. Wolkentsein, S. Culine, P. Combemale, Laurence Valeyrie-Allanore, D. Pouessel, D. Hamel-Teillac, and Y. Perel
- Subjects
Dermatology - Published
- 2012
44. Combined Chemoradiation Therapy With Gemcitabine and Cisplatinum for Organ Preservation in Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial
- Author
-
O. Riou, S. Culine, X. Rebillard, S. Thezenas, A. Faix, B. Segui, D. Pouessel, and D. Azria
- Subjects
Cancer Research ,Radiation ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2012
45. Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)
- Author
-
S. Xiong, J. D. Wesley, F. Rolland, S. Chan, Bradley C. Carthon, L. G. Garcia, M. Fenner, Linda Sharp, Frank Priou, R. Morales-Barrera, W. Gerritsen, Bernhard J. Eigl, M. Tod, A.J.M. van den Eertwegh, Lawrence Fong, D. Baertschi, Arnoud J. Templeton, J.N. Graff, J. Morote, C. G. O'Bryan-Tear, Mert Basaran, S. Dixit, L. Mourey, J.P. Fusco, James B. Trager, C. Arbayo, Z. Peng, E. Solsona, D. D. Tsao-Wei, David P. Dearnaley, M. Hirmand, G. Procopio, M. Hancock, E. Verzoni, Eric Winquist, L. Shen, A. Sella, R. Tang, E. Ileana, J. A. Rinck, J.-G. Judde, B. Mellado, J. Simko, Martin E. Gleave, A. G. Caamano, Maha Hussain, Shaw Ling Wang, V. Ortega, L. Nicacio, Omar Esteban Carranza, D. G. Power, Frances P. Stewart, L. Bourre, Lawrence Karsh, B. Bennett, R. van Gool, S. Moran, M. Schulze, G. C. Cedermark, B. Esterni, Sophie D. Fosså, R. N. Dass, Guru Sonpavde, Anthony M. Joshua, B. A. Blumenstein, Christophe Massard, Andre Deeke Sasse, C. Suarez, D. Hawes, M. Marin-Aguilera, J. Lackey, M. Sharma, V. Pasov, J. T. Dalton, G. Velasco, G. Liu, J. Li, M. I. Murdock, D. Rathkopf, P. Vrignaud, R. Strebel, F. de Braud, Karim Fizazi, P. Raina, Linda Zinoli, V. De Angelis, A. J. Lloyd, B. Laguerre, S. Hitier, F. Vazquez, L. Zubiri, G. Maier, H. Lannert, M. A. Johnston, Stéphane Oudard, S.J. Hotte, X. Zhou, Nancy A. Dawson, Michael E. Cox, S. Donegani, M. Sisani, Jeffrey R. Gingrich, J. M. Ferrero, C. Papandreou, J. B. Whitmore, R. Sands, Q. Wang, Matthew R. Smith, C. Theodore, P. Perrin, P. M. Hoff, C. S.-L. Thibault, J.S. de Bono, J. Droz, Steinbjørn Hansen, M. A. Morgan, John M. Corman, P. Tryon, M. Climent, S. Berry, C. W. M. Reuter, A. Ozcimen, G. De Castro, T. Sella, G. Geiges, I. Kocak, U. Anido, Y. Hao, N. Bedini, Tanya B. Dorff, María E. Zudaire, David Smith, S. Li, Mansoor N. Saleh, M. Junqueira, I. Krakowski, Nadeem A. Sheikh, G. Sanchez-Olle, Raymond S. McDermott, G. Deplanque, Marianna de Camargo Cancela, L. Bellardita, W. Ye, R. Valdagni, J. Pinski, Nina Tunariu, C. Cavaliere, T. Devries, Silke Gillessen, Vasileios J. Assikis, Christopher J. Logothetis, K. Staudacher, A. Bahl, G. Chodak, R. Wei, Pasquale Rescigno, T. Shahid, M. Taplin, L. Ahrlund-Richter, Chadi Nabhan, N. Batista, Simon J. Hall, A. Heidenreich, Deborah Mukherji, Kim N. Chi, S. Zanetta, Ethan Basch, C. Kim, M. Haggman, Kurt Miller, S. Crowe, L. G. Fonseca, M. Nister, V. Grunwald, David I. Quinn, P. Cabrera, J. Wong, Peter F.A. Mulders, Noah M. Hahn, E. Levesque, W. Liu, Chris Parker, I. Gil-Aldea, I. Testa, Shahneen Sandhu, F. Ricci, N. Sacks, J. E. Brown, Eric J. Small, A. Ganser, C. Pezaro, S. Boccardo, E. Small, C. V. Morales, R. P. Taylor, Przemyslaw Twardowski, W. R. Clark, L. M. A. Aparicio, David Olmos, D. E. Castellano, Phillip Parente, R. Delva, A. Sanchez, Michael L. Meyers, A. Ruffion, P. Gascon, J. R. Gingerich, U. Harmenberg, D. Pouessel, Joshi J. Alumkal, L. Reyno, M. Spencer, S. Neibart, C. Korn, M. Habibian, Hazem I. Assi, J. Sarantopoulos, J. Charpentier, J. Squire, Christian Rothermundt, J. Versluis, G. Liskovsky, Saskia J. A. M. Santegoets, Maria Jose Lechuga, A. Hamzaj, E. Arevalo, Andrew J. Armstrong, Steven M. Larson, V. Naini, F. Kueppers, H. Ozen, R. Barroso-Sousa, C.J. Amling, Andrea L. Harzstark, L. Puglia, S. Bracarda, S. Le Moulec, S. Hubay, S. V. Liu, A. Horchani, L. Lui, F. Joly Lobbedez, S. Del Buono, S. Basu, N. Tiftik, D. Nicolle, P. de Souza, G. Freyer, T. Magnani, E. Benaim, E. Y. Yu, V. Yvonnet, N. Rozumna-Martynyuk, S. Salvi, P. Samper, M. S. N. M. Sharial, R. Salvioni, J. G. Gandhi, O. Terekhov, Elizabeth Eisenhauer, G. Gravis, I. Bodrogi, J. Lin, I. N. Boyko, B. Zhang, Patricia Martin, S. Kovel, Eleni Efstathiou, A. Cross, S. Villa, Cora N. Sternberg, Vivian Weinberg, M. Soulie, J. Zou, M. Wilbaux, David B. Agus, Yohann Loriot, C. Goessl, A. Stam, I. De Torres, D. W. Davis, M. Hjelm-Eriksson, P. Federico, J. E. Garcia-Vargas, M. Gedamke, Philip W. Kantoff, A. Petremolo, F. Marrocolo, B. Perez-Valderrama, G. Mordenti, X. Maldonado, P. Hamberg, Roberto Pili, M. Doherty, K. Hege, Pier Vitale Nuzzo, Winald R. Gerritsen, D. P. Petrylak, L. Ji, O. A. Sartor, Leonard G. Gomella, Sumanta K. Pal, J. Bruce, Scott North, Mario A. Eisenberger, Robert E. Coleman, Diletta Bianchini, E. Henin, Michael A. Carducci, A. G. Omlin, S. De Placido, A. Liede, J. Good, A. Hartford, Richard Cathomas, Anna C. Ferrari, S. S. Sridhar, Alessandra Rubagotti, A. C. R. Chaves, P. Sieber, L. O. Reis, D. Lin, A. Arican, Y. Zhang, O. Nordle, J. Tito, G. Bhattacharyya, V. Melnikova, N. Aucoin, P. W. Price, Susan Ellard, P. Beuzeboc, K. Noonan, A. A. Ranade, M. W. Frohlich, B. Anand, K. Buyukafsar, William R. Berry, Mitchell S. Steiner, D. Raghavan, Daniel J. George, C. D. L. Piedra, Gregory R. Pond, F. Acosta, A. O. Sartor, A. Yildirim, G. Di Lorenzo, Thomas W. Griffin, P. M. Parikh, Harry Comber, Matthew D. Galsky, A. J. Armstrong, J. M. Fitzpatrick, M. Legrier, J. R. Piulats, Neal D. Shore, Walter M. Stadler, J. Powers, R. J. Amato, S. O'Reilly, G. B. Kanaka, M. Girard, N. Nicolai, D. Maillet, C. Piatek, Robert H. Getzenberg, Dana E. Rathkopf, J. Eymard, E. C. Alvarez, S. Wong, H. Kurt, Elisabeth I. Heath, R. C. Winterhalder, T. Zoubir, A. Tagliapietra, I. N. Hernandez, Oliver Sartor, H. Malhotra, Amir Goldkorn, E. J. Leonard, J. M. Wolff, Ronald F. Tutrone, Charles S. Cleeland, Q. Perez, A. Ulyanov, Christopher Sweeney, Mustafa Ozguroglu, Jolanda Paolini, I. Lowy, Ignacio Gil-Bazo, C. Dzik, Fred Saad, William Oh, L. Skoog, S. Stagni, Emmanuel S. Antonarakis, Maria J. Ribal, C. L. Nourani, E. Chow-Maneval, J-P. Machiels, K. Anderes, Shannon Matheny, T. de La Motte Rouge, A. Ata, Celestia S. Higano, Malcolm David Mason, Heather Haynes, L. Sengelov, M. Poupon, S. Nilsson, K. Jelaca-Maxwell, R. A. Stephenson, Thian Kheoh, Howard I. Scher, S. Groshen, P. Schellhammer, Y. Pawitan, C. Li, C. D'Aniello, A. Olsson, Michael Pollak, T. Harding, I. Latorzeff, Ralph J. Hauke, Arturo Molina, Paul N. Mainwaring, J. J. Lozano, F. McDonnell, B. You, R. B. Sims, P. Carroll, Z. I. Malik, Joan Carles, Ainhoa Castillo, D. T. Castro, M.D. Michaelson, T.D. de Gruijl, Joaquim Bellmunt, N. Houede, Manisha Singh, A. Guillot, A. M. Cassidy, Charles J. Ryan, E. Esteban, M. Truini, Laurence Albiges, C. Buonerba, O. Gunther, G. Forsberg, Bryan Selby, Paul G. Corn, B. A. Wood, J. K. Singh, Michael J. Morris, J. Biswas, M. Gross Goupil, Francesco Boccardo, W. de Schultz, P. Czaykowski, Nicholas J. Vogelzang, M. Y. Teo, P. Afzal, and Gerhardt Attard
- Subjects
medicine.medical_specialty ,Genitourinary system ,business.industry ,Standard treatment ,Hazard ratio ,Urology ,Hematology ,medicine.disease ,Androgen deprivation therapy ,Prostate cancer ,medicine.anatomical_structure ,Oncology ,Docetaxel ,Prostate ,medicine ,Clinical endpoint ,business ,medicine.drug - Abstract
Background Androgen deprivation therapy (ADT) is the standard treatment of hormone-sensitive metastatic prostate cancer (HSMPC). We performed a phase III multicentre trial to compare ADT alone with ADT plus docetaxel (D) in HNMPC. Methods Patients (pts) with HSMPC were randomly assigned to either arm A (ADT + D: 75mg/m q3w, up to 9 cycles) or arm B (ADT). The primary endpoint was overall survival (OS). The planned number of pts was 378 to detect an improvement in OS with a hazard ratio (HR) of 0.62, a power of 80% and an alpha risk of 0.05 (two-sided test). Secondary endpoints were biological progression-free survival (PFS) and clinical PFS. Data on toxicity and quality of life have been previously presented. Results From October 2004 to December 2008, 385pts were included. Baseline characteristics were well balanced between the two arms. Median age was 63 years (43-84), median PSA was 26.4 ng/ml (0.1-11900), Gleason score was ≥ 8 in 57%. Prognostic classification was as follows: good prognosis (49%), intermediate (29%) and poor (22%). The majority of pts had metastases at the time of diagnosis (72%), 28% developed metastases after local treatment failure. Median number of D cycles was 8 (range 0-9). The median follow-up was 50 months (mo) [95%CI: 49-54]. At 6 mo, a higher PSA response (≥ 50%) in arm A (94% vs 85%, p = 0.0096) and a higher PSA progression (≥ 25%) in arm B (10% vs 1%, p = 0.0015) were observed. Biological PFS was significantly longer in arm A: 22.9 vs 12.9 mo, HR; 0.72 [95%CI: 0.57-0.91] (p = 0.005). Clinical PFS was increase in arm A: 23.46 vs 15.44 mo, HR: 0.75 [95CI: 0.59-0.94] (0.015). OS was not significantly different (median: 58.9 mo in arm A and 54.2 mo in arm B, HR: 1.01 [95%CI: 0.75-1.36]. The median OS for each prognostic group was 69.1 [95%CI: 60.9-NR], 46.5 [95%CI: 37.7-NR] and 36.6 [95%CI9: 28.5-58.9] mo respectively in the good, intermediate, and poor prognosis groups (p = 0.001), with no difference between the two arms. At the cut-off time, 65% of pts from the ADT arm had received docetaxel since they developed castrate-resistant prostate cancer. Conclusion Combining docetaxel and ADT improves PFS over ADT alone in pts with HSMPC. However, no difference in OS was observed between the two arms. Disclosure G. Gravis: I have expert testimony to disclose: Sanofi Aventis, uncompensated. K. Fizazi: Participation to advisory boards and speaker for Sanofi-Aventis. F. Joly Lobbedez: advisory board/board of directors position: Sanofi, Roche, Pfizer, Novartis, Ferring; compensated consultant relationship: Roche, Novartis; honoraria: Sanofi, Roche, Pfizer, Novartis, Ferring, Ipsen,Takeda; travel remuneration: ASCO by Novartis, ESMO by Janssen. S. Oudard: I have an advisory relationship and honoraria to disclose: Pfizer Oncology, Bayer-Schering Pharma, Hoffman La Roche, Glaxo SmithKline, Novartis Pharma, Sanofi Aventis. D. Pouessel: Consultant role and honoraria: Sanofi, P. Beuzeboc: Presentations: Avantis, All other authors have declared no conflicts of interest.
- Published
- 2012
46. Cancérologie - Caractéristiques des métastatses hépatiques de cancer primitif inconnu
- Author
-
D. Pouessel
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Medicine ,General Medicine ,business - Published
- 2006
47. Syndrome de Good et pneumopathie à cytomégalovirus
- Author
-
D Pouessel, L. Landreau, C. Pelle, P. Corne, A Makinson, M.Ben Hadj Salem, and Olivier Jonquet
- Subjects
Ganciclovir ,Hypogammaglobulinemia ,Thymoma ,business.industry ,Gastroenterology ,Internal Medicine ,medicine ,Congenital cytomegalovirus infection ,Cytomegalovirus infections ,medicine.disease ,business ,Virology ,medicine.drug - Published
- 2003
48. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
- Author
-
Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, Christelle, Rios, Maria, Abadie-Lacourtoisie, Sophie, Venat-Bouvet, Laurence, Cany, Laurent, Catala, Stéphanie, Khayat, David, Gambotti, Laetitia, Pauporté, Iris, Faure-Mercier, Céline, Paget-Bailly, Sophie, Henriques, Julie, Grouin, Jean Marie, Centre Paul Strauss, CRLCC Paul Strauss, CRLCC Val d'Aurelle - Paul Lamarque, Institut Bergonié [Bordeaux], UNICANCER, Institut Curie [Paris], Université Paris Descartes - Paris 5 (UPD5), CRLCC Eugène Marquis (CRLCC), Centre Léon Bérard [Lyon], Centre Catherine-de-Sienne [Nantes] (CCS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Sainte Catherine [Avignon], Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne, CRLCC Jean Godinot, Institut Jean Godinot [Reims], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), CHU Limoges, Clinique Francheville [Périgueux], CHU Saint-Pierre, Clinique Bizet [Pais], Institut national du cancer [Boulogne] (INCA), Ligue Nationale Contre le Cancer - Paris, Ligue Nationale Contre le Cancer (LNCC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Unité de biostatistiques [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), The French National Cancer Institute, PHARE trial investigators: C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, J L Bréau, A K Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, J L Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, A F Dillies, X Durando, J P Ferrière, C Mouret-Reynier, J M Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, A C Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, J P Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, J M Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, J M Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, J C Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, H Roché, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, A Hocini, G Sadki-Benaoudia, A Marti, A L Villing, B Slama, J L Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, M J Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, J C Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, E Guardiola, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, J F Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, J Ezenfis, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, J Meunier, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, J F Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, L Cals, P Nouyrigat, S Clippe, M C Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, J Grenier, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, L Dupuy-Brousseau, D Fric, C Garnier, C Leyronnas, T Kreitman, R Largillier, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, J F Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, J P Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, J C Legueul, J Mandet, D Besson, A C Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, J M Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, C B Levaché, G Auclerc, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, G A Baumont, M Bégue, S Gréget, J L Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, J Cretin, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, J L Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, J P Chantelard, G A L'Helgoualc'h, E C Antoine, A Kanoui, J F Llory, J M Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, K Mahour-Bacha, N Barbet, N Dohollou, K Yakendji, CCSD, Accord Elsevier, and Ligue Nationnale Contre le Cancer
- Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,skin and connective tissue diseases - Abstract
International audience; Background: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned final analysis based on the prespecified number of occurring events.Methods: PHARE is an open-label, phase 3, non-inferiority randomised trial of patients with HER2-positive early breast cancer comparing 6 months versus 12 months of trastuzumab treatment concomitant with or following standard neoadjuvant or adjuvant chemotherapy. The study was undertaken in 156 centres in France. Eligible patients were women aged 18 years or older with non-metastatic, operable, histologically confirmed adenocarcinoma of the breast and either positive axillary nodes or negative axillary nodes but a tumour of at least 10 mm. Participants must have received at least four cycles of a chemotherapy for this breast cancer and have started receiving adjuvant trastuzumab-treatment. Eligible patients were randomly assigned to either 6 months or 12 months of trastuzumab therapy duration between the third and sixth months of adjuvant trastuzumab. The randomisation was stratified by concomitant or sequential treatment with chemotherapy, oestrogen receptor status, and centre. The primary objective was non-inferiority in the intention-to-treat population in the 6-month group in terms of disease-free survival with a prespecified hazard margin of 1·15. This trial is registered with ClinicalTrials.gov, number NCT00381901.Findings: 3384 patients were enrolled and randomly assigned to either 12 months (n=1691) or 6 months (n=1693) of adjuvant trastuzumab. One patient in the 12-month group and three patients in the 6-month group were excluded, so 1690 patients in each group were included in the intention-to-treat analysis. At a median follow-up of 7·5 years (IQR 5·3-8·8), 704 events relevant to disease-free survival were observed (345 [20·4%] in the 12-month group and 359 [21·2%] in the 6-month group). The adjusted hazard ratio for disease-free survival in the 12-month group versus the 6-month group was 1·08 (95% CI 0·93-1·25; p=0·39). The non-inferiority margin was included in the 95% CI. No differences in effects pertaining to trastuzumab duration were found in any of the subgroups. After the completion of trastuzumab treatment, rare adverse events occurred over time and the safety analysis remained similar to the previously published report. In particular, we found no change in the cardiac safety comparison, and only three additional cases in which the left ventricular ejection fraction decreased to less than 50% have been reported in the 12-month group.Interpretation: The PHARE study did not show the non-inferiority of 6 months versus 12 months of adjuvant trastuzumab. Hence, adjuvant trastuzumab standard duration should remain 12 months.
- Published
- 2019
49. Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.
- Author
-
Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Fléchon A, Jain RK, Swami U, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jürgensmeier JM, and Tagawa ST
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Aged, 80 and over, Adult, Biomarkers, Tumor metabolism, Urologic Neoplasms drug therapy, Urologic Neoplasms pathology, Urologic Neoplasms mortality, Urologic Neoplasms metabolism, Treatment Outcome, Neoplasm Staging, Cell Adhesion Molecules metabolism, Antigens, Neoplasm, Antibodies, Monoclonal, Humanized therapeutic use, Camptothecin analogs & derivatives, Camptothecin therapeutic use, Immunoconjugates therapeutic use
- Abstract
Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2-directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1-3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression., Patients and Methods: TROPHY-U-01 (NCT03547973) is an open-label phase II study that assessed the efficacy and safety of SG (alone or in combinations) in patients with unresectable locally advanced or metastatic UC (mUC). Archival tumor samples collected at enrollment for C1-3 were analyzed for Trop-2 membrane expression by considering histological scores (H-scores; scale 0-300) and the percentage of membrane positive tumor cells at low magnification (4×). The association of Trop-2 with clinical endpoints [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)] was evaluated., Results: In C1-3, tissue was collected from 158 (82%) of 192 treated patients, and 146 (76%) had evaluable Trop-2 data. Trop-2 was highly expressed in tumor samples. The median [interquartile range (IQR)] Trop-2 H-score was 215 (180-246), and the median (IQR) percentage of membrane positive tumor cells was 91% (80-98). Trop-2 expression at any level was observed in 98% of patients. Furthermore, ORR, PFS, and OS benefits were observed across all Trop-2 expression levels., Conclusions: Trop-2 protein is highly expressed in UC, as confirmed by examining tumors from patients enrolled in the TROPHY-U-01 trial. The results indicate that SG demonstrates efficacy in mUC across Trop-2 expression levels., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
50. Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy.
- Author
-
van Gennep EJ, Claps F, Bostrom PJ, Shariat SF, Neuzillet Y, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Bussani R, Burger M, Boormans JL, Wullich B, Hartmann A, Mayr R, Pavan N, Bartoletti R, Mir MC, Pouessel D, van der Hoeven J, van der Kwast TH, Allory Y, Zuiverloon TCM, Lotan Y, and van Rhijn BWG
- Abstract
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed., Objectives: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection., Methods: We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers. LN-densitywas calculated as the ratio of the number of positive LNs×100% to the number of LNs removed. The optimal LN-density cut-off value was defined by creating a time-dependent receiver operating characteristic (ROC) curve in pN patients. Univariable and multivariable Cox' regression analyses were used to assess the effect of conventional Tumor Nodes Metastasis (TNM) nodal staging system, LN-density and other LN-related variables on DSS in the pN-positive cohort., Results: Of the 1169 patients, 463 (39.6%) patients had LN-involvement. The area under the ROC curve was 0.60 and the cut-off for LN-density was set at 20%, 223 of the pN-positive patients (48.2%) had a LN-density ≥ 20%. In multivariable models, the number of LN-metastases (HR 1.03, p = 0.005) and LN-density, either as continuous (HR 1.01, p = 0.013) or as categorical variable (HR 1.37, p = 0.014), were independently associated with worse DSS, whereas pN-stage was not., Conclusions: LN-density ≥ 20% was an independent predictor of worse DSS in BC patients with LN-involvement at RC. The integration of LN-density and other LN-parameters rather than only conventional pN-stage may contribute to a more refined risk-stratification in BC patients with nodal involvement., Competing Interests: BWGvR, SFS, ARZ, AH, TCMZ and YL are Editorial Board Members of this journal but were blinded and not involved in the peer-review process nor had access to any information regarding its peer-review. Peter J. Bostrom: Peter Bostrom reports research grant from Juselius Foundation and Cancer Foundation Finland. Additionally, consultation fees from Astellas and Janssen are reported. Shahrokh. F. Shariat: S.F. Shariat reports advisory board of/and or speaker for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lissy, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia and Sanofi. Joost L. Boormans: JL Boormans received travel grants from Combat medical to attend scientific meetings and has received honoraria by MSD, Roche, BMS and Janssen Pharmaceuticals for consultancy work. Yair Lotan: Y Lotan reported consultancy for Nanorobotics, C2I genomics, Photocure, Astra-Zeneca, Merck, Fergene, Abbvie, Nucleix, Ambu, Seattle Genetics, Hitachi, Ferring Research, verity pharmaceutics, virtuoso surgical, Stimit, Urogen, Vessi medical, CAPs medical, Xcures, BMS, Nonagen, Aura Biosciences, Inc., Convergent Genomics, Pacific Edge, Pfizer, Phinomics Inc, CG oncology, Uroviu, On target lab. Bas WG van Rhijn: BWG van Rhijn reported Advisory board meetings: QED Therapeutics and Incyte International Biosciences. The remaining authors reported no further conflicts of interest., (© 2024 – The authors. Published by IOS Press.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.